Clinical trials: Anaphylactic Reaction, open to volunteers
- Condition Anaphylactic Reaction
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Peanut-Induced Anaphylaxis, Peanut Allergy
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies.
- Trial name
- UKK-0018 (NCT07349212)
- Testing
- UKK-0018
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 40 people
- Sponsor
- Ukko Inc
Epinephrine, Hypersensitivity, Immediate
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
This Phase 2, open-label, single-arm study will evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose of epinephrine nasal spray (ENS) in children and adolescents 2 to 17 years of age with a…
- Conditions
- Epinephrine, Hypersensitivity, Immediate, Anaphylaxis
- Trial name
- NCT07891780
- Testing
- Epinephrine Nasal Spray, 2.5 mg, Epinephrine Nasal Spray, 5.25 mg
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Hikma Pharmaceuticals USA Inc.
Hypersensitivity Reactions
Post-market Safety Study of LUMISIGHT
This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associated with LUMISIGHT (pegulicianine) administration in adults with…
- Trial name
- NCT07572162
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Lumicell, Inc.
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex…
- Trial name
- NCT06746883
- Testing
- Non-interventional
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Innoviva Specialty Therapeutics
Anaphylaxis Food
FMXIN002 in Patients at Risk of Anaphylaxis
Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis. Study Design Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more…
- Trial name
- NCT07045701
- Testing
- Epinephrine 4mg nasal powder spray, Adrenalin 0.5mg Injectable Product
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Nasus Pharma
Anaphylaxis, Allergy
Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
The study will evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) responses of FMXIN002, an intranasal epinephrine powder, compared with the EpiPen® intramuscular autoinjector, after single and double doses, in healthy…
- Trial name
- NCT07228325
- Testing
- FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma